Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. The ... Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. The company specializes in antibody discovery and protein engineering to create differentiated therapeutic candidates targeting previously validated drug targets in established disease areas. Viridian is primarily focused on therapies for thyroid eye disease (TED), advancing multiple clinical candidates including veligrotug (VRDN-001) and VRDN-003, both undergoing pivotal phase 3 trials worldwide. Beyond TED, Viridian is developing a portfolio of neonatal Fc receptor (FcRn) inhibitors aimed at treating multiple autoimmune diseases. The company strives to improve treatment options by offering therapies that are safe, effective, and easy to use for people affected by autoimmune and rare diseases. Viridian maintains a strong financial position to support its clinical programs and commercial preparations, highlighting its significant role in the biopharmaceutical market addressing unmet medical needs in rare and autoimmune conditions.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Financial Fundamentals data not yet covered for Viridien

We have not yet reviewed Viridien's disclosures for Financial Fundamentals data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Viridien's data?

Create a free Tracenable account to signal interest in having our team review data for Viridien.

Legal Center Contact Us